The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial safety and efficacy of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in combination with pembrolizumab in patients with recurrent or metastatic (R/M) HNSCC.
 
Maura Gillison
Consulting or Advisory Role - Abbvie; Adaptimmune; Aptitude Health; Axiom Biotechnologies; Bayer; Bicara Therapeutics; Bicara Therapeutics; BioNTech; BioNTech; BioNTech SE; Boxer Capital; Brightly Network; Bristol-Myers Squibb; Bristol-Myers Squibb/Roche; Caladrius Biosciences; Coherus Biosciences; Coherus Biosciences; Debiopharm Group; Eisai; EMD Serono; EMD Serono; EMD Serono; END Merck; Exelixis; Gilead Sciences; Guidepoint Global; Ipsen; Istari; ITeos Therapeutics; Journal of Clinical Oncology; Kura Oncology; LLX Solutions; LLX Solutions; Merck; Merus; Merus; Mirati Therapeutics; Nektar; OncLive; Pfizer; Seagen; Sensei Biotherapeutics; Shattuck Labs; Surface Oncology; Suzhou Liangyihui Network Technology; Takeda
Research Funding - Abbvie (Inst); Agenus (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Cullinan Oncology (Inst); Genentech (Inst); Genocea Biosciences (Inst); Gilead Sciences (Inst); INVAX (Inst); Kura Oncology (Inst); Merck (Inst); Merus (Inst); NRG Oncology (Inst); Roche (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - PCT/US2022/023911 pending Board of Regents, The University of Texas System
 
Marc Oliva
Honoraria - Bristol-Myers Squibb/Pfizer; Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology; Transgene
Consulting or Advisory Role - Merck KGaA; MSD Oncology; MSD Oncology; Obatica
Research Funding - ALX Oncology (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Merck; MSD Oncology (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology
Other Relationship - Merck; MSD Oncology
 
Christophe Le Tourneau
Honoraria - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Novartis; Rakuten Medical; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD
 
Ramy Saleh
No Relationships to Disclose
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Daiichi Sankyo, Inc.; Genentech/Roche (I); Gilead Sciences; HalioDx; Ionova; Janssen; Loxo; Merck; MERCK (I); Novartis; Pfizer; Pfizer; Quanta Therapeutics; Scorpion Therapeutics; Seagen; Silverback Therapeutics
Speakers' Bureau - Merck
Research Funding - 1200 Pharma (Inst); AADi (Inst); Abbvie (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); BioTheryX (Inst); Bolt Biotherapeutics (Inst); Carrick Therapeutics (Inst); Compugen (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); IGM Biosciences (Inst); Infinity Pharmaceuticals (Inst); Institut de Recherches Internationales Servier (I.R.I.S) (Inst); Ionova (Inst); Ionova (Inst); Klus Pharma (Inst); KSQ Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Loxo@Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); MOMA Therapeutics (Inst); Nektar (Inst); Olema Oncology (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Pyrotec Therapeutics (Inst); Quanta Therapeutics (Inst); Sanofi (Inst); Scorpion Therapeutics (Inst); Seagen (Inst); Seagen (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst)
 
Jonathan Riess
Consulting or Advisory Role - Amgen; Bicycle Therapeutics; Bristol-Myers Squibb/Celgene; Catalyst Clinical Research; Daiichi Sankyo; Genentech; GlaxoSmithKline; Janssen Oncology; Merck; Merus NV; Oncohost; Pfizer; Regeneron; Replimune
Research Funding - ArriVent Biopharma (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); IO Biotech (Inst); Kinnate Biopharma (Inst); Merck (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Pfizer; Revolution Medicines (Inst); Summit pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; IO Biotech
 
Neeltje Steeghs
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene; Ellipses Pharma (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst); Incyte; Incyte (Inst)
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CellCentric (Inst); Cogent Biosciences (Inst); Crescendo Biologics (Inst); Daiichi Sankyo/Lilly (Inst); Daiichi Sankyo/Lilly (Inst); Deciphera (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Iambic (Inst); IDRx (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Kling Biotherapeutics (Inst); Lixte Biotechnology (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Molecular Partners (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche (Inst); Sanofi (Inst); Zentalis (Inst)
 
Justin Call
No Relationships to Disclose
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie/Stemcentrx; Amgen; AstraZeneca; Tempus
Research Funding - Abbvie/Stemcentrx (Inst); Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Ipsen (Inst); Lilly/ImClone (Inst); Mirati Therapeutics (Inst); Seagen (Inst); Takeda (Inst)
 
Elisa Fontana
Employment - HCA/Sarah Cannon
Leadership - European Organisation for Research and Treatment of Cancer (EORTC)
Consulting or Advisory Role - Astellas Pharma; Bicycle Therapeutics; BMS; Erasca, Inc; Pfizer
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carrick Therapeutics (Inst); CASI Pharmaceuticals (Inst); Clovis Oncology (Inst); Crescendo Biologics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Ellipses Pharma (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fore Biotherapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); HUTCHMED (Inst); Ignyta/Genentech/Roche (Inst); Immunocore (Inst); Immunomedics (Inst); Incyte (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Kronos Bio (Inst); Lilly (Inst); Lupin Pharmaceuticals (Inst); Macrogenics (Inst); Menarini (Inst); Merck KGaA (Inst); Mereo Biopharma (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Nerviano Medical Sciences (Inst); Nurix (Inst); Oxford VacMedix (Inst); Pfizer (Inst); Plexxikon (Inst); PMV Pharma (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Roche (Inst); Sapience Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Stemline Therapeutics (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Bicycle Therapeutics; Caris Life Sciences; Erasca, Inc; Repare Therapeutics; Sapience Therapeutics; Seagen
 
Arjun Oberoi
No Relationships to Disclose
 
Nuria Kotecki
Research Funding - BMS GmbH & Co. KG (Inst)
Travel, Accommodations, Expenses - Byondis; ose pharma; Pfizer
 
Anna Minchom
Honoraria - GlaxoSmithKline; Janssen; Merck; Seagen; Takeda
Consulting or Advisory Role - AstraZeneca; Faron Pharmaceuticals; GlaxoSmithKline; Immutep; Janssen Oncology; Merck; MSD; Pfizer
Research Funding - Astex Pharmaceuticals (Inst); Merck (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Sebastian Ochsenreither
Honoraria - AstraZeneca; BMS; immunocore; Janssen Oncology; Merck Serono; MSD
Consulting or Advisory Role - Immatics; immunocore; Janssen-Cilag; MSD; Pfizer
Research Funding - Bayer (Inst)
Patents, Royalties, Other Intellectual Property - Cyclin A1 as T-cell target
Travel, Accommodations, Expenses - Janssen Oncology; Merck Serono; Pfizer
Other Relationship - Ipsen
 
Kaïssa Ouali
Consulting or Advisory Role - Amgen; Anaveon; Sotio
Travel, Accommodations, Expenses - Amgen; Eisai; Sotio
 
Anna Spreafico
Consulting or Advisory Role - Alentis Therapeutics; Bristol-Myers Squibb; GlaxoSmithKline; Merck
Research Funding - Alentis Therapeutics (Inst); Alkermes (Inst); ALX Oncology (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Nubiyota (Inst); Pfizer (Inst); Replimune (Inst); Roche (Inst); Seagen (Inst); SERVIER (Inst); Symphogen (Inst); Teva (Inst); Treadwell Therapeutics (Inst)
 
Andrea Zivi
No Relationships to Disclose
 
Shivani Gupta
No Relationships to Disclose
 
Rong Zhang
No Relationships to Disclose
 
Lisle Nabell
No Relationships to Disclose